89
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

, , , , , , , & show all
Pages 527-535 | Published online: 13 Oct 2015

References

  • AguadoJMRuiz-CampsIMuñozPGuidelines for the treatment of invasive candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 UpdateEnferm Infecc Microbiol Clin201129345361 Spanish21459489
  • PfallerMADiekemaDJEpidemiology of invasive candidiasis: a persistent public health problemClin Microbiol Rev20072013316317223626
  • AlmiranteBRodríguezDParkBJEpidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003J Clin Microbiol2005431829183515815004
  • BouzaEMuñozPEpidemiology of candidemia in intensive care unitsInt J Antimicrob Agents200832Suppl 2S87S9119013346
  • OlaecheaPMPalomarMLeón-GilCEconomic impact of Candida colonization and Candida infection in the critically ill patientEur J Clin Microbiol Infect Dis20042332333015024623
  • LortholaryOPetrikkosGAkovaMESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDSClin Microbiol Infect201218Suppl 7687723137138
  • KuseERChetchotisakdPda CunhaCAMicafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialLancet20073691519152717482982
  • DupontBFLortholaryOOstrosky-ZeichnerLStuckerFYeldandiVTreatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin BCrit Care200913R15919804626
  • MillsEJPerriDCooperCAntifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysisAnn Clin Microbiol Antimicrob200982319558681
  • LortholaryORenaudatCSitbonKWorrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010)Intensive Care Med2014401303131225097069
  • Puig-AsensioMPadillaBGarnacho-MonteroJEpidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in SpainClin Microbiol Infect201420O245O25424125548
  • PemánJZaragozaRTowards an early diagnosis of invasive candidiasis in the critically ill patientRev Iberoam Micol2012297175 Spanish22463780
  • WangJLChangCHYoung-XuYChanKASystematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infectionAntimicrob Agents Chemother2010542409241920308378
  • US Food Drug AdministrationCancidas (caspofungin acetate) [prescribing information]2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021227s031lbl.pdfAccessed July 13, 2014
  • PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis20094850353519191635
  • GrauSSalavertMCarlos Pozo LaderasJGarcía VargasMBarruetaJAMirNCost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in SpainJ Mycol Med20132315516323849341
  • BlascoAJLlibreJMArribasJRAnalysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013Enferm Infecc Microbiol Clin201331568578 Spanish23969276
  • BOT Plus 2.0 [website on the Internet]Consejo General de Colegios de Farmacéuticos Available from: https://botplusweb.portalfarma.comAccessed June 16, 2014
  • Agencia Española de Medicamentos y Productos SanitariosEcalta 100 mg [summary of product characteristics] Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/07416002/FT_07416002.pdfAccessed June 16, 2014 Spanish
  • Agencia Española de Medicamentos y Productos SanitariosMycamine 50 mg [summary of product characteristics] Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/08448001/FT_08448001.pdfAccessed June 16, 2014 Spanish
  • Agencia Española de Medicamentos y Productos SanitariosCancidas 50 mg [summary of product characteristics] Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/01196001/FT_01196001.pdfAccessed June 16, 2014 Spanish
  • Agencia Española de Medicamentos y Productos SanitariosFluconazol B. Braun 2 mg/mL [summary of product characteristics] Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/71461/FT_71461.pdfAccessed June 16, 2014 Spanish
  • Agencia Española de Medicamentos y Productos SanitariosAmbisome 50 mg [summary of product characteristics] Available from: http://www.aemps.gob.es/cima/pdfs/es/ft/61117/FT_61117.pdfAccessed June 16, 2014 Spanish
  • García-VargasMCasadoMAMirNBarruetaJACost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in SpainFarm Hosp201236207215 Spanish22118764
  • ReboliACRotsteinCPappasPGAnidulafungin versus fluconazole for invasive candidiasisN Engl J Med20073562472248217568028
  • PappasPGRotsteinCMBettsRFMicafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasisClin Infect Dis20074588389317806055
  • Mora-DuarteJBettsRRotsteinCComparison of caspofungin and amphotericin B for invasive candidiasisN Engl J Med20023472020202912490683
  • KullbergBJSobelJDRuhnkeMVoriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomised non-inferiority trialLancet20053661435144216243088
  • BriggsAClaxtonKSculpherMDecision Modelling for Health Economic EvaluationOxfordOxford University Press2006
  • ChenSCSlavinMASorrellTCEchinocandin antifungal drugs in fungal infections: a comparisonDrugs201171114121175238
  • Rubio-TerrésCSacristánJABadiaXCoboEGarcía AlonsoFMethods to perform economic assessments of health interventionsMed Clin (Barc)2004122578583 Spanish15144747
  • Rubio-TerrésCCoboESacristánJAPrietoLdel LlanoJBadiaXAnalysis of uncertainty in the economic assessment of health interventionsMed Clin (Barc)2004122668674 Spanish15153348
  • SacristánJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit20021633434312113733
  • WilkeMTreatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literatureEur J Med Res20111618018621486732
  • ReboliACRotsteinCKettDHResource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patientsPharmacoeconomics20112970571721591820
  • AuzingerGPlayfordGGrahamCCost-effectiveness analysis of anidulafungin in the treatment of candidaemiaCrit Care201317Suppl 2P87
  • NeohCFLiewDSlavinMCost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasisJ Antimicrob Chemother2011661906191521628305